Théa Pharmaceuticals has received FDA approval for Iyuzeh (latanoprost ophthalmic solution) 0.005% for elevated intraocular pressure (IOP) reduction in open-angle glaucoma and ocular hypertension.
What is unique about Iyuzeh?
Iyuzeh (EYE-YOU-ZUH) is the first and only clinically proven formulation of latanoprost available in the United States that is preservative-free.
How does it work?
The formulation is designed as a single dosage to be placed in the eye(s) once daily in the evening. After administration, IOP reduction takes approximately 3 to 4 hours to begin. The maximum level of effect takes place after 8 to 12 hours. From start to finish, IOP reduction remains for at least 24 hours. (via)
What did clinical trials show?
Two randomized clinical trials found that Iyuzeh lowered IOP by 3 to 8 mmHg in comparison to 4 to 8 mmHg by a preservative-formulated solution (benzalkonium chloride). The most common adverse reactions reported were conjunctival hyperemia (34%) and eye irritation (19%).
When can we prescribe this?
Théa expects to commercially launch Iyuzeh in the U.S. by the second half of 2023.